Lifitegrast
FDA-approved product (solution/drops, ophthalmic), marketed as Lifitegrast, Xiidra.
- Registered studies
- 39
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Dry eye syndrome
- Eye disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other ophthalmologicals
- FDA pharmacologic class
- Lymphocyte Function-Associated Antigen-1 Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
39registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lifitegrast with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness
NCT03686878 · start 2016-12-16
Registered record
- Registry ID
- NCT03686878
- Conditions
- Contact Lens; Contact Lens Discomfort; Contact Lens Dryness
- Interventions
- Lifitegrast
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-12-16
- Completion
- 2017-07-14
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContact Lens; Contact Lens Discomfort; Contact Lens DrynessInterventionLifitegrastPhasePhase 4Registry statusCompletedEffect of Lifitegrast on Dry Eye Disease Signs and Symptoms
NCT03451396 · start 2016-12-12
Registered record
- Registry ID
- NCT03451396
- Conditions
- Dry Eye
- Interventions
- Lifitegrast
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-12-12
- Completion
- 2018-03-15
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry EyeInterventionLifitegrastPhasePhase 4Registry statusCompletedA Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
NCT02284516 · start 2014-11-06
Registered record
- Registry ID
- NCT02284516
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-11-06
- Completion
- 2015-10-05
- Enrolment
- 711
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedA Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
NCT01743729 · start 2012-12-07
Registered record
- Registry ID
- NCT01743729
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-12-07
- Completion
- 2013-10-01
- Enrolment
- 720
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedSafety Study of Lifitegrast to Treat Dry Eye
NCT01636206 · start 2012-10-16
Registered record
- Registry ID
- NCT01636206
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-10-16
- Completion
- 2014-03-03
- Enrolment
- 332
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedSafety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
NCT01421498 · start 2011-08-29
Registered record
- Registry ID
- NCT01421498
- Conditions
- Keratoconjunctivitis Sicca; Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-08-29
- Completion
- 2012-04-28
- Enrolment
- 588
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKeratoconjunctivitis Sicca; Dry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedA Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
NCT00926185 · start 2009-08-03
Registered record
- Registry ID
- NCT00926185
- Conditions
- Dry Eye
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-08-03
- Completion
- 2010-02-18
- Enrolment
- 230
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry EyeInterventionLifitegrast; PlaceboPhasePhase 2Registry statusCompletedSAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
NCT00936520 · start 2009-08
Registered record
- Registry ID
- NCT00936520
- Conditions
- Diabetic Macular Edema (DME); Pars Plana Vitrectomy
- Interventions
- SAR 1118 0.1%; SAR 1118 1.0%; SAR 1118 5.0%
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2009-08
- Completion
- 2010-05
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic Macular Edema (DME); Pars Plana VitrectomyInterventionSAR 1118 0.1%; SAR 1118 1.0%; SAR 1118 5.0%PhasePhase 1Registry statusTerminatedEfficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
NCT00882687 · start 2009-04-24
Registered record
- Registry ID
- NCT00882687
- Conditions
- Allergic Conjunctivitis
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-04-24
- Completion
- 2009-05-10
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic ConjunctivitisInterventionLifitegrast; PlaceboPhasePhase 2Registry statusCompleted